
Sign up to save your podcasts
Or


In this week's technology spotlight, Dr. Bob Traynor speaks with Abhita Batra, CEO and Director of Otomagnetics. The company, a University of Maryland College Park spin-out, is developing a non-invasive method to deliver drugs and other therapeutic payloads to inner and middle ear compartments, to the eye, and into the skin.
The inner ear is behind the blood-labyrinth barrier – vessels that supply blood to the inner ear have walls that are impermeable to most drug molecules, and thus it is a challenge to deliver therapy to treat inner ear diseases. Otomagnetics is developing and commercializing a magnetic injection delivery system that will be able to safely, effectively, and non-invasively deliver therapy to targets in the body that are currently not effectively reached by the standards-of-care, or that may otherwise require surgery to reach.
By This Week in Hearing5
11 ratings
In this week's technology spotlight, Dr. Bob Traynor speaks with Abhita Batra, CEO and Director of Otomagnetics. The company, a University of Maryland College Park spin-out, is developing a non-invasive method to deliver drugs and other therapeutic payloads to inner and middle ear compartments, to the eye, and into the skin.
The inner ear is behind the blood-labyrinth barrier – vessels that supply blood to the inner ear have walls that are impermeable to most drug molecules, and thus it is a challenge to deliver therapy to treat inner ear diseases. Otomagnetics is developing and commercializing a magnetic injection delivery system that will be able to safely, effectively, and non-invasively deliver therapy to targets in the body that are currently not effectively reached by the standards-of-care, or that may otherwise require surgery to reach.

38,519 Listeners

9,507 Listeners

30,234 Listeners

87,153 Listeners

112,327 Listeners

24,680 Listeners

8,618 Listeners

5,441 Listeners

20 Listeners

58,231 Listeners

167 Listeners

1,058 Listeners